OBJECTIVES: Severe hyperglycemia and/or hypoglycemia risks post-discharge can increase diabetes readmission rates. Therefore, the selection of glucose management strategies after discharge is crucial for glycemic control.

METHODS: Collecting data from 52 inpatient T2DM patients admitted from May 2022 to December 2023, with a 6-month follow-up. Evaluating the effectiveness and safety of different insulin treatment regimens. Statistical analysis was performed using SPSS 25.0.

RESULTS: Among 52 T2DM patients, 13 patients were treated with basal insulin and 39 patients were premixed insulin. There were no significant differences between two groups in terms of gender, age, systolic and diastolic blood pressure, LDL-C, HDL-C, TC, and TG (p > 0.05). Baseline HbA1c and FPG levels were 9.76±1.44% and 7.39±1.29 mmol/L, respectively, in the basal group, and 10.05±2.08% and 7.30±1.57 mmol/L, respectively, in the premixed group (p > 0.05).At 6 months, the HbA1c levels were significantly lower in the basal group (6.65±0.83%) compared to the premixed group (7.28±1.30%, p=0.048). FPG levels did not differ significantly between the groups; they were 6.73±1.27 mmol/L in the basal group and slightly lower than in the premixed group (7.65±2.31 mmol/L), but the difference was not statistically significant (p=0.364). The proportion of patients experiencing symptomatic hypoglycemia (FPG < 70 mg/dL) was lower in the basal group (7.7%) compared to the premixed group (15.4%).

CONCLUSIONS: For T2DM patients, basal insulin appears to be an effective and safe treatment option. Increasing the sample size for further exploration could be beneficial.